RapamycinFungusV1, Main, Exploration, bibRecord, 001890

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Identifieur interne : 001890 ( Main/Exploration ); précédent : 001889; suivant : 001891

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Auteurs : William J. Steinbach [États-Unis] ; Nina Singh ; Jackie L. Miller ; Daniel K. Benjamin ; Wiley A. Schell ; Joseph Heitman ; John R. Perfect

Source :

Antimicrobial agents and chemotherapy [ 0066-4804 ] ; 2004.

RBID : pubmed:15561883

Descripteurs français

KwdFr :
- Amphotéricine B (pharmacologie), Antifongiques (pharmacologie), Aspergillose (traitement médicamenteux), Aspergillus fumigatus (effets des médicaments et des substances chimiques), Caspofungine (MeSH), Ciclosporine (pharmacologie), Humains (MeSH), Immunosuppresseurs (pharmacologie), Inhibiteurs de la calcineurine (MeSH), Lipopeptides (MeSH), Peptides cycliques (pharmacologie), Pyrimidines (pharmacologie), Tacrolimus (pharmacologie), Transplantation d'organe (MeSH), Triazoles (pharmacologie), Voriconazole (MeSH), Échinocandines (MeSH).
MESH :
- effets des médicaments et des substances chimiques : Aspergillus fumigatus.
- pharmacologie : Amphotéricine B, Antifongiques, Ciclosporine, Immunosuppresseurs, Peptides cycliques, Pyrimidines, Tacrolimus, Triazoles.
- traitement médicamenteux : Aspergillose.
- Caspofungine, Humains, Inhibiteurs de la calcineurine, Lipopeptides, Transplantation d'organe, Voriconazole, Échinocandines.

English descriptors

KwdEn :
- Amphotericin B (pharmacology), Antifungal Agents (pharmacology), Aspergillosis (drug therapy), Aspergillus fumigatus (drug effects), Calcineurin Inhibitors (MeSH), Caspofungin (MeSH), Cyclosporine (pharmacology), Echinocandins (MeSH), Humans (MeSH), Immunosuppressive Agents (pharmacology), Lipopeptides (MeSH), Organ Transplantation (MeSH), Peptides, Cyclic (pharmacology), Pyrimidines (pharmacology), Tacrolimus (pharmacology), Triazoles (pharmacology), Voriconazole (MeSH).
MESH :
- chemical , pharmacology : Amphotericin B, Antifungal Agents, Cyclosporine, Immunosuppressive Agents, Peptides, Cyclic, Pyrimidines, Tacrolimus, Triazoles.
- drug effects : Aspergillus fumigatus.
- drug therapy : Aspergillosis.
- chemical : Calcineurin Inhibitors, Caspofungin, Echinocandins, Humans, Lipopeptides, Organ Transplantation, Voriconazole.

Abstract

We performed in vitro antifungal checkerboard testing on 12 Aspergillus fumigatus clinical isolates (6 transplant recipients and 6 nontransplant patients) with three antifungal agents (amphotericin B, voriconazole, and caspofungin) and three immunosuppressants (FK506, cyclosporine, and rapamycin). We were not able to detect a difference in calcineurin inhibitor antifungal activity against isolates from transplant recipients and nontransplant patients.

DOI: 10.1128/AAC.48.12.4922-4925.2004
PubMed: 15561883
PubMed Central: PMC529228

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 001868
to stream Main, to step Curation: 001868

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.</title>
<author><name sortKey="Steinbach, William J" sort="Steinbach, William J" uniqKey="Steinbach W" first="William J" last="Steinbach">William J. Steinbach</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA. stein022@mc.duke.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710</wicri:regionArea>
<wicri:noRegion>North Carolina 27710</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Singh, Nina" sort="Singh, Nina" uniqKey="Singh N" first="Nina" last="Singh">Nina Singh</name>
</author>
<author><name sortKey="Miller, Jackie L" sort="Miller, Jackie L" uniqKey="Miller J" first="Jackie L" last="Miller">Jackie L. Miller</name>
</author>
<author><name sortKey="Benjamin, Daniel K" sort="Benjamin, Daniel K" uniqKey="Benjamin D" first="Daniel K" last="Benjamin">Daniel K. Benjamin</name>
</author>
<author><name sortKey="Schell, Wiley A" sort="Schell, Wiley A" uniqKey="Schell W" first="Wiley A" last="Schell">Wiley A. Schell</name>
</author>
<author><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name>
</author>
<author><name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R" last="Perfect">John R. Perfect</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15561883</idno>
<idno type="pmid">15561883</idno>
<idno type="doi">10.1128/AAC.48.12.4922-4925.2004</idno>
<idno type="pmc">PMC529228</idno>
<idno type="wicri:Area/Main/Corpus">001868</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001868</idno>
<idno type="wicri:Area/Main/Curation">001868</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001868</idno>
<idno type="wicri:Area/Main/Exploration">001868</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.</title>
<author><name sortKey="Steinbach, William J" sort="Steinbach, William J" uniqKey="Steinbach W" first="William J" last="Steinbach">William J. Steinbach</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA. stein022@mc.duke.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710</wicri:regionArea>
<wicri:noRegion>North Carolina 27710</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Singh, Nina" sort="Singh, Nina" uniqKey="Singh N" first="Nina" last="Singh">Nina Singh</name>
</author>
<author><name sortKey="Miller, Jackie L" sort="Miller, Jackie L" uniqKey="Miller J" first="Jackie L" last="Miller">Jackie L. Miller</name>
</author>
<author><name sortKey="Benjamin, Daniel K" sort="Benjamin, Daniel K" uniqKey="Benjamin D" first="Daniel K" last="Benjamin">Daniel K. Benjamin</name>
</author>
<author><name sortKey="Schell, Wiley A" sort="Schell, Wiley A" uniqKey="Schell W" first="Wiley A" last="Schell">Wiley A. Schell</name>
</author>
<author><name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name>
</author>
<author><name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R" last="Perfect">John R. Perfect</name>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amphotericin B (pharmacology)</term>
<term>Antifungal Agents (pharmacology)</term>
<term>Aspergillosis (drug therapy)</term>
<term>Aspergillus fumigatus (drug effects)</term>
<term>Calcineurin Inhibitors (MeSH)</term>
<term>Caspofungin (MeSH)</term>
<term>Cyclosporine (pharmacology)</term>
<term>Echinocandins (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunosuppressive Agents (pharmacology)</term>
<term>Lipopeptides (MeSH)</term>
<term>Organ Transplantation (MeSH)</term>
<term>Peptides, Cyclic (pharmacology)</term>
<term>Pyrimidines (pharmacology)</term>
<term>Tacrolimus (pharmacology)</term>
<term>Triazoles (pharmacology)</term>
<term>Voriconazole (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Amphotéricine B (pharmacologie)</term>
<term>Antifongiques (pharmacologie)</term>
<term>Aspergillose (traitement médicamenteux)</term>
<term>Aspergillus fumigatus (effets des médicaments et des substances chimiques)</term>
<term>Caspofungine (MeSH)</term>
<term>Ciclosporine (pharmacologie)</term>
<term>Humains (MeSH)</term>
<term>Immunosuppresseurs (pharmacologie)</term>
<term>Inhibiteurs de la calcineurine (MeSH)</term>
<term>Lipopeptides (MeSH)</term>
<term>Peptides cycliques (pharmacologie)</term>
<term>Pyrimidines (pharmacologie)</term>
<term>Tacrolimus (pharmacologie)</term>
<term>Transplantation d'organe (MeSH)</term>
<term>Triazoles (pharmacologie)</term>
<term>Voriconazole (MeSH)</term>
<term>Échinocandines (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Amphotericin B</term>
<term>Antifungal Agents</term>
<term>Cyclosporine</term>
<term>Immunosuppressive Agents</term>
<term>Peptides, Cyclic</term>
<term>Pyrimidines</term>
<term>Tacrolimus</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Aspergillus fumigatus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Aspergillosis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Aspergillus fumigatus</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Amphotéricine B</term>
<term>Antifongiques</term>
<term>Ciclosporine</term>
<term>Immunosuppresseurs</term>
<term>Peptides cycliques</term>
<term>Pyrimidines</term>
<term>Tacrolimus</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Aspergillose</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Calcineurin Inhibitors</term>
<term>Caspofungin</term>
<term>Echinocandins</term>
<term>Humans</term>
<term>Lipopeptides</term>
<term>Organ Transplantation</term>
<term>Voriconazole</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Caspofungine</term>
<term>Humains</term>
<term>Inhibiteurs de la calcineurine</term>
<term>Lipopeptides</term>
<term>Transplantation d'organe</term>
<term>Voriconazole</term>
<term>Échinocandines</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We performed in vitro antifungal checkerboard testing on 12 Aspergillus fumigatus clinical isolates (6 transplant recipients and 6 nontransplant patients) with three antifungal agents (amphotericin B, voriconazole, and caspofungin) and three immunosuppressants (FK506, cyclosporine, and rapamycin). We were not able to detect a difference in calcineurin inhibitor antifungal activity against isolates from transplant recipients and nontransplant patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15561883</PMID>
<DateCompleted><Year>2005</Year>
<Month>01</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0066-4804</ISSN>
<JournalIssue CitedMedium="Print"><Volume>48</Volume>
<Issue>12</Issue>
<PubDate><Year>2004</Year>
<Month>Dec</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation>
</Journal>
<ArticleTitle>In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.</ArticleTitle>
<Pagination><MedlinePgn>4922-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>We performed in vitro antifungal checkerboard testing on 12 Aspergillus fumigatus clinical isolates (6 transplant recipients and 6 nontransplant patients) with three antifungal agents (amphotericin B, voriconazole, and caspofungin) and three immunosuppressants (FK506, cyclosporine, and rapamycin). We were not able to detect a difference in calcineurin inhibitor antifungal activity against isolates from transplant recipients and nontransplant patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steinbach</LastName>
<ForeName>William J</ForeName>
<Initials>WJ</Initials>
<AffiliationInfo><Affiliation>Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA. stein022@mc.duke.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Singh</LastName>
<ForeName>Nina</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Miller</LastName>
<ForeName>Jackie L</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Benjamin</LastName>
<ForeName>Daniel K</ForeName>
<Initials>DK</Initials>
<Suffix>Jr</Suffix>
</Author>
<Author ValidYN="Y"><LastName>Schell</LastName>
<ForeName>Wiley A</ForeName>
<Initials>WA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Heitman</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Perfect</LastName>
<ForeName>John R</ForeName>
<Initials>JR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R56 AI028388</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>1 R03 HD42940-02</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R03 HD042940</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI-50438</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI054719</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI028388</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>1 R01 AI054719-01</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI-28388</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K12 HD000850</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K12-HD00850</GrantID>
<Acronym>HD</Acronym>
<Agency>NICHD NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P01-AI-449175</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AI050438</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D065095">Calcineurin Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054714">Echinocandins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D055666">Lipopeptides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7XU7A7DROE</RegistryNumber>
<NameOfSubstance UI="D000666">Amphotericin B</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83HN0GTJ6D</RegistryNumber>
<NameOfSubstance UI="D016572">Cyclosporine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>F0XDI6ZL63</RegistryNumber>
<NameOfSubstance UI="D000077336">Caspofungin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>JFU09I87TR</RegistryNumber>
<NameOfSubstance UI="D065819">Voriconazole</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber>
<NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000666" MajorTopicYN="N">Amphotericin B</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001228" MajorTopicYN="N">Aspergillosis</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001232" MajorTopicYN="N">Aspergillus fumigatus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065095" MajorTopicYN="N">Calcineurin Inhibitors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000077336" MajorTopicYN="N">Caspofungin</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016572" MajorTopicYN="N">Cyclosporine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054714" MajorTopicYN="N">Echinocandins</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055666" MajorTopicYN="N">Lipopeptides</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016377" MajorTopicYN="Y">Organ Transplantation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010456" MajorTopicYN="N">Peptides, Cyclic</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065819" MajorTopicYN="N">Voriconazole</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>11</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>1</Month>
<Day>19</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>11</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15561883</ArticleId>
<ArticleId IdType="pii">48/12/4922</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.48.12.4922-4925.2004</ArticleId>
<ArticleId IdType="pmc">PMC529228</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 1998 Apr;26(4):781-803; quiz 804-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9564455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1997 May 15;16(10):2576-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9184205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cornea. 1999 May;18(3):306-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10336034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 1999 Oct;12(4):583-611</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10515904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2000 Jan;44(1):143-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10602736</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 2000 Feb;68(2):982-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10639477</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2000 Mar;44(3):739-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10681348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2000 Sep;44(9):2373-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10952582</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2000 Nov;44(11):2932-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11036003</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2001 Jan;45(1):327-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11120990</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2001 Mar 30;276(13):9583-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11266435</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 2001 Sep 21;276(38):35875-82</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11451958</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2001 Nov;45(11):3162-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11600372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 2002 Feb 15;21(4):546-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11847103</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2002 Apr 1;34(7):909-17</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11880955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioessays. 2002 Oct;24(10):894-903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12325122</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2003 Jan 1;36(1):46-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12491201</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2003 Feb;51(2):313-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12562696</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2003 Mar;47(3):956-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12604527</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Investig Drugs. 2003 Feb;4(2):192-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12669381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2003 May;47(5):1565-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12709323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Microbiol. 2003 May;48(4):959-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12753189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S157-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12975751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2004 May;48(5):1664-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15105118</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 1987 Feb;106(2):209-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3541723</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 1991 Aug 23;66(4):807-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1715244</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transplantation. 1994 Jun 27;57(12):1689-700</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7517076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 1996 Jul;33(1):23-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8842991</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1997 Jan;41(1):156-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8980772</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 1998 Dec;42(6):747-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10052898</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><noCountry><name sortKey="Benjamin, Daniel K" sort="Benjamin, Daniel K" uniqKey="Benjamin D" first="Daniel K" last="Benjamin">Daniel K. Benjamin</name>
<name sortKey="Heitman, Joseph" sort="Heitman, Joseph" uniqKey="Heitman J" first="Joseph" last="Heitman">Joseph Heitman</name>
<name sortKey="Miller, Jackie L" sort="Miller, Jackie L" uniqKey="Miller J" first="Jackie L" last="Miller">Jackie L. Miller</name>
<name sortKey="Perfect, John R" sort="Perfect, John R" uniqKey="Perfect J" first="John R" last="Perfect">John R. Perfect</name>
<name sortKey="Schell, Wiley A" sort="Schell, Wiley A" uniqKey="Schell W" first="Wiley A" last="Schell">Wiley A. Schell</name>
<name sortKey="Singh, Nina" sort="Singh, Nina" uniqKey="Singh N" first="Nina" last="Singh">Nina Singh</name>
</noCountry>
<country name="États-Unis"><noRegion><name sortKey="Steinbach, William J" sort="Steinbach, William J" uniqKey="Steinbach W" first="William J" last="Steinbach">William J. Steinbach</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001890 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001890 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:15561883
   |texte=   In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:15561883" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki